colonoscopy semaglutide Troubling Findings in Study of GLP-1 Compounders Getting to the heart of

In addition, researchers have found that those taking GLP-1 drugs like Ozempic have a: 9.09 times higher risk of pancreatitis

The PIONEER program (Peptide InnOvatioN for the Early diabEtes tReatment) comprised 10 individual trials comparing once-daily oral semaglutide with placebo (six studies) or active comparator in different populations (1421, 23, 24)

Note that 2/3 of the weight lost by the participants was regained within a year of stopping treatment with semaglutide

It was limited by the lack of conclusive reports detailing the reaction, lack of re-administration, lack of toxic levels detected, and the potential for an unknown alternative diagnosis to be the source of the reaction

Metabolic Rate Effects: Some research suggests GIP may influence energy expenditure, though this is still being studied

doi: 10.2337/dc15-1437 112 BaggioLLUssherJRMcLeanBACaoXKabirMGMulvihillEEet al